Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Alkermes plc News

    23,93 $ -2,92% -0,72 $
    In : 22,337 € | 16:44:54 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1JKVH
    ISIN: IE00B56GVS15
    US-Symbol: ALKS
    Typ: Aktie

    Warnung
    Dieses Wertpapier ist nicht mehr aktuell.

    Alkermes plc News

    24.04.24 - PR Newswire
    Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
    Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 PR Newswire
    24.04.24 - PR Newswire
    Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
    Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 PR Newswire
    17.04.24 - PR Newswire
    Alkermes to Report First Quarter Financial Results on May 1, 2024
    Alkermes to Report First Quarter Financial Results on May 1, 2024 PR Newswire
    17.04.24 - PR Newswire
    Alkermes to Report First Quarter Financial Results on May 1, 2024
    Alkermes to Report First Quarter Financial Results on May 1, 2024 PR Newswire
    09.04.24 - PR Newswire
    Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
    Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic ...
    09.04.24 - PR Newswire
    Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
    Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic ...
    08.04.24 - PR Newswire
    Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
    Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society PR ...
    08.04.24 - PR Newswire
    Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
    Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society PR ...
    07.03.24 - PR Newswire
    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors PR Newswire
    07.03.24 - PR Newswire
    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors PR Newswire
    15.02.24 - PR Newswire
    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 PR Newswire
    15.02.24 - PR Newswire
    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 PR Newswire
    08.02.24 - PR Newswire
    Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
    Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 PR Newswire
    08.02.24 - PR Newswire
    Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
    Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 PR Newswire
    03.01.24 - PR Newswire
    Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
    03.01.24 - PR Newswire
    Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
    03.01.24 - PR Newswire
    Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
    Alkermes Announces Topline Results From Long-Term, Open-​Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan) PR Newswire
    03.01.24 - PR Newswire
    Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
    Alkermes Announces Topline Results From Long-Term, Open-​Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan) PR Newswire
    14.12.23 - PR Newswire
    Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
    Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk PR Newswire
    14.12.23 - PR Newswire
    Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
    Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk PR Newswire

    Newssuche

    Videos

    09:30 Uhr +53,66%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »